sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Implantable Cardioverter Defibrillators Market Size Study by Product Type, by Type, by NYHA Class, by End-use and Regional Forecasts 2024-2032

Global Implantable Cardioverter Defibrillators Market Size Study by Product Type,...

Home / Categories / Healthcare
Global Implantable Cardioverter Defibrillators Market Size Study by Product Type, by Type, by NYHA Class, by End-use and Regional Forecasts 2024-2032
Global Implantable Cardioverter Defibrillators Market...
Report Code
RO1/103/3221

Publish Date
16/Oct/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
Global Implantable Cardioverter Defibrillators (ICD) Market is valued approximately at USD 3.81 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.4% over the forecast period 2024-2032. The Implantable Cardioverter Defibrillator (ICD) represents a significant technological advancement in the field of cardiology, designed to monitor and regulate heart rhythms in patients at high risk of sudden cardiac arrest. The device is implanted under the skin, near the heart, and works by detecting dangerous arrhythmias such as ventricular tachycardia or fibrillation, and promptly delivering electrical shocks to restore a normal heart rhythm. The demand for ICDs is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) globally, which are on the rise due to factors such as aging populations, sedentary lifestyles, and other associated risk factors. These devices are crucial in the ongoing management of patients with a history of life-threatening arrhythmias or heart failure, significantly improving survival rates.

The Global ICD Market is bolstered by continuous technological advancements, including the development of MRI-compatible ICDs, devices with longer battery life, and smaller, less invasive models. These innovations not only enhance the safety and efficacy of ICDs but also increase their adoption among patients and healthcare providers. Additionally, growing awareness of sudden cardiac arrest and the critical role ICDs play in preventing these events, coupled with government initiatives aimed at reducing the burden of cardiovascular diseases, are expected to further drive market growth. These factors, combined with the expansion of healthcare infrastructure in emerging markets, present substantial opportunities for market expansion.

The Global ICD Market is also poised for growth due to the aging global population, which is a key demographic at higher risk of cardiovascular diseases. As the number of elderly individuals continues to increase, the demand for ICDs is expected to grow correspondingly. However, challenges such as the high cost of ICDs, including the expenses related to implantation procedures and follow-up care, may hinder market growth, particularly in regions with limited healthcare funding or where patients lack adequate health insurance.

North America accounted for the largest share of the global market in 2023, representing 41.4% of the total market value. The region's dominance is attributed to its advanced healthcare infrastructure, high prevalence of CVDs, and the presence of leading market players such as Medtronic, Abbott, and Boston Scientific. Medtronic's recent introduction of extravascular ICDs (EV-ICDs), which offer promising clinical efficacy in treating ventricular arrhythmias and tachycardia, highlights the region's leadership in this field. Conversely, the Asia-Pacific region is anticipated to experience the fastest growth during the forecast period, driven by the high prevalence of CVDs in countries like China, India, and Japan, alongside rapid advancements in healthcare technology.

Major market players included in this report are:
Medtronic
Boston Scientific
Abbott Laboratories
Biotronik
Philips Healthcare
Sorin Group (now part of LivaNova)
Zoll Medical Corporation
Nihon Kohden Corporation
MicroPort Scientific Corporation
LivaNova
The detailed segments and sub-segments of the market are explained below:
By Product Type:
Transvenous Implantable Cardioverter-Defibrillators
Subcutaneous Implantable Cardioverter Defibrillators
By Type:
Single Chamber ICDs
Dual Chamber ICDs
Biventricular Devices
By NYHA Class:
NYHA Class II
NYHA Class III
By End-use:
Hospitals
Ambulatory Surgical Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com